Get Support – Call 1-888-MITO-411

Stealth BioTherapeutics MMPOWER-2 and REPOWER Study Update

Print Friendly, PDF & Email

Stealth BioTherapeutics patient/community update on MMPOWER-2 and RePOWER Primary Mitochondrial Myopathy clinical trials

Stealth’s CEO Reenie McCarthy and Chief Clinical Development Officer Jim Carr shares updates on Stealth’s second clinical trial for mitochondrial myopathy, the MMPOWER-2 study.

Join us for this free webinar to learn more about:

  • Safety and tolerability data of elamipretide (previously known as Bendavia) from the MMPOWER-2 study
  • Tests and assessments used to measure efficacy of elamipretide in the MMPOWER-2 trial
  • Endpoints and outcomes from the MMPOWER-2 trial for people ages 16-65 with genetically-confirmed mitochondrial myopathy
  • Future Stealth BT studies evaluating elamipretide and mitochondrial myopathy
  • All are welcome and encouraged to listen to this live presentation. An opportunity to submit questions online will be provided during the live webinar.
Event Summary

About the Speaker

Reenie McCarthy

Reenie McCarthy

Reenie McCarthy is the Chief Executive Officer and a member of the Board of Stealth BioTherapeutics. Reenie is a 20+ year veteran of the investment team of Morningside, Stealth’s principal investor, with extensive experience working with private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic areas.

James Carr

James Carr

Jim Carr is the Chief Clinical Development Officer of Stealth BioTherapeutics. He brings over 20 years of industry experience in the areas of clinical development, medical affairs, lifecycle management, new product planning, and global marketing to Stealth. Previously, Jim was an Executive Director in the Global Cardiovascular Franchise at GlaxoSmithKline. Prior to GlaxoSmithKline, Jim held the role of Vice President of Clinical Development at Arca Biopharma. During Jim’s time in industry, his efforts have centered on cardiovascular drug development, with a specific focus on heart failure. Jim’s educational background is a Doctor of Pharmacy degree from the University of Minnesota and post-graduate training in clinical cardiovascular pharmacology. Prior to joining the pharmaceutical industry, Jim was on the clinical faculty at the University at Buffalo-SUNY School of Pharmacy.

Upcoming Events

View All
View Calendar

Expert Series

View All
View Calendar

Last Presentation

Expert Series: Ins and Outs of the Mito Cocktail: Pat 1 of 2
Presented November 21, 2024

P.O. Box 310
Novi, MI 48376
(888) 648-6228
info@mitoaction.org